Daehan New Pharm Co (XKRX:054670) Cash-to-Debt : 0.66 (As of Sep. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Daehan New Pharm Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Daehan New Pharm Co's cash to debt ratio for the quarter that ended in Sep. 2024 was 0.66.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Daehan New Pharm Co couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Daehan New Pharm Co's Cash-to-Debt or its related term are showing as below:

XKRX:054670' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05 Med: 0.39 Max: 1.03
Current: 0.66

During the past 13 years, Daehan New Pharm Co's highest Cash to Debt Ratio was 1.03. The lowest was 0.05. And the median was 0.39.

XKRX:054670's Cash-to-Debt is ranked worse than
56.56% of 1022 companies
in the Drug Manufacturers industry
Industry Median: 0.935 vs XKRX:054670: 0.66

Daehan New Pharm Co Cash-to-Debt Historical Data

The historical data trend for Daehan New Pharm Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Daehan New Pharm Co Cash-to-Debt Chart

Daehan New Pharm Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.49

0.54

0.61

0.80

0.65

Daehan New Pharm Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															1.03	0.65	0.76	0.50	0.66

Competitive Comparison of Daehan New Pharm Co's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Daehan New Pharm Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daehan New Pharm Co's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daehan New Pharm Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Daehan New Pharm Co's Cash-to-Debt falls into.

Daehan New Pharm Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Daehan New Pharm Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	23780.077	/	(36228.575	+	369.212)
	=	0.65

Daehan New Pharm Co's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	35016.811	/	(40301.495	+	12999.79)
	=	0.66

Daehan New Pharm Co (XKRX:054670) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Daehan New Pharm Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Daehan New Pharm Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Daehan New Pharm Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daehan New Pharm Co Ltd (XKRX:054670) » Definitions » Cash-to-Debt

Traded in Other Exchanges

N/A

Address

1062-4 Namhyeon-dong, Gwanak-gu, Seoul, KOR, 137-851

Website

http://www.dhnp.co.kr

Daehan New Pharm Co Ltd is a South Korea based company operating in the pharmaceutical sector. It is engaged in producing pharmaceutical products, animal health and nutrition, and bio products. The pharmaceutical products are tertan tab, amloc tab, tarocin SR tab, NP star tab and others. The animal health and nutrition products are starvac, pigcoc for calves, ocean doctor, and others. The bio range of the products by the group are CELRENA serum-free, BMPro serum-free, BMPro-V serum-free, ALyS505NK-EX serum-free and others.

Daehan New Pharm Co Headlines

No Headlines